These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3877147)

  • 61. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
    Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.
    Heikkila RE; Hess A; Duvoisin RC
    Science; 1984 Jun; 224(4656):1451-3. PubMed ID: 6610213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MPTP and convulsive responses in rodents.
    Fariello RG; DeMattei M; Castorina M; Ferraro TN; Golden GT
    Brain Res; 1987 Nov; 426(2):373-6. PubMed ID: 3500756
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sershen H; Reith ME; Hashim A; Lajtha A
    Eur J Pharmacol; 1984 Jun; 102(1):175-8. PubMed ID: 6332738
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine.
    Fuller RW; Hemrick-Luecke SK; Robertson DW
    Biochem Pharmacol; 1988 Sep; 37(17):3343-7. PubMed ID: 3135812
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP.
    Eldridge R; Rocca WA
    N Engl J Med; 1985 Oct; 313(18):1159-60. PubMed ID: 3876508
    [No Abstract]   [Full Text] [Related]  

  • 67. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro.
    Bocchetta A; Piccardi MP; Del Zompo M; Pintus S; Corsini GU
    J Neurochem; 1985 Sep; 45(3):673-6. PubMed ID: 3928808
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.
    Linder JC; Klemfuss H; Groves PM
    Neurosci Lett; 1987 Nov; 82(2):221-6. PubMed ID: 3501082
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP; Neff NH
    Neurosci Lett; 1988 Oct; 92(2):207-12. PubMed ID: 2903475
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of several dopaminergic drugs and trihexyphenidyl on cholinergic parameters in the rat striatum.
    Consolo S; Ladinsky H; Garattini S
    J Pharm Pharmacol; 1974 Apr; 26(4):275-7. PubMed ID: 4151386
    [No Abstract]   [Full Text] [Related]  

  • 71. Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats.
    Heikkila RE; Nicklas WJ; Duvoisin RC
    Neurosci Lett; 1985 Aug; 59(1):135-40. PubMed ID: 2413402
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) accelerates the accumulation of lipofuscin in mouse adrenal gland.
    Hadjiconstantinou M; Tjioe S; Alho H; Miller C; Neff NH
    Neurosci Lett; 1987 Dec; 83(1-2):1-6. PubMed ID: 3502018
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs.
    Andén NE
    J Pharm Pharmacol; 1972 Nov; 24(11):905-6. PubMed ID: 4405656
    [No Abstract]   [Full Text] [Related]  

  • 74. PC12 variants deficient in catecholamine transport.
    Bitler CM; Zhang MB; Howard BD
    J Neurochem; 1986 Oct; 47(4):1286-93. PubMed ID: 3489073
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A comparison of the inhibitory effects of certain antiparkinsonian agents on dopamine accumulation into the rat striatum.
    Nose T; Segawa T
    Jpn J Pharmacol; 1974 Apr; 24(2):299-305. PubMed ID: 4152745
    [No Abstract]   [Full Text] [Related]  

  • 76. Differences in the stereospecificity of closely related compounds; a reinvestigation of the enantiomers of procyclidine, benzhexol and their metho- and etho-salts.
    Barlow RB
    J Pharm Pharmacol; 1971 Feb; 23(2):90-7. PubMed ID: 4396885
    [No Abstract]   [Full Text] [Related]  

  • 77. Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of parkinsonism.
    Wong C; Ishibashi T; Tucker G; Hamasaki D
    Exp Eye Res; 1985 Apr; 40(4):509-19. PubMed ID: 2988989
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structure of a Neurotoxin that Induces Parkinsonism Symptoms; l-Methyl-4-phenyl-l,2,3,6-tetra-hydropyridine Hydrochloride.
    Klein CL; Borne RF; Stevens ED
    Pharm Res; 1985 Jul; 2(4):192-4. PubMed ID: 24272814
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacology of a new anti-parkinsonian drug: KAO-264.
    Kojima M; Nose T; Shintomi K; Yoneda N
    Jpn J Pharmacol; 1971 Apr; 21(2):276-9. PubMed ID: 4996373
    [No Abstract]   [Full Text] [Related]  

  • 80. Chemicopharmacological studies on antispasmodic action. V. Fundamental conditions of bioassay of acetylcholine and atropine on the isolated small intestines of mice.
    TAKAGI K; KIMURA M
    Pharm Bull; 1956 Dec; 4(6):444-9. PubMed ID: 13408083
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.